EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting Arrhythmogenic Late Sodium Current by FHF1 A -Derivative FixR in Heart Failure Cardiomyocytes

Targeting Arrhythmogenic Late Sodium Current by FHF1 A-Derivative FixR in Heart Failure Cardiomyocytes

Bence Hegyi iD, Paweorn Angsutararux iD, Nourdine Chakouri iD, Ryan W Mahling, Lucile Fossier iD, Hai M Nguyen iD, Shannon Gilhooly, Victor Alencar Almeida iD, Charlotte E R Smith iD, Lianguo Wang iD, Crystal M Ripplinger iD, Jody L Martin iD und 5 weitere

Circulation Research · 06.07.2026 · 139 (2)

DOI: 10.1161/circresaha.126.328204 ↗

Auf einen Blick

In Herzinsuffizienz war der späte Natriumstrom erhöht und die FHF-Spleißisoform-Expression verändert. Der Peptidwirkstoff FixR senkte den pathologischen I Na,L und wirkte antiarrhythmisch in Zell- und Mausmodellen.

Fragestellung

Kann das aus FHF1 A abgeleitete Peptid FixR den erhöhten späten Natriumstrom bei Herzinsuffizienz gezielt hemmen und arrhythmogene Veränderungen reduzieren?

Methode

Untersuchung in humanem HFrEF-Gewebe sowie in Rabbit- und Mausmodellen von HFrEF und HFpEF; Test von FixR an Kardiomyozyten und in vivo in transgenen Mäusen mit CaMKIIδ C-Überexpression.

Ergebnisse

In failing hearts waren FHF-Langisoformen vermindert. FixR reduzierte pathologischen I Na,L in HFrEF und HFpEF, ohne Einfluss auf Peak-Na+, L-Typ-Ca2+- oder wichtige K+-Ströme. Zudem nahm die Arrhythmieanfälligkeit ab.

Schlussfolgerung der Autor:innen

In Herzinsuffizienz ist I Na,L erhöht und die FHF-Spleißisoform-Expression verändert. FixR ist ein potenter und selektiver I Na,L-Inhibitor mit antiarrhythmischen Eigenschaften in HFrEF- und HFpEF-Kardiomyozyten.

Kernaussagen

  • FixR senkte den pathologischen späten Natriumstrom in HFrEF und HFpEF
  • Keine Wirkung auf Peak-Na+, L-Typ-Ca2+- oder wichtige K+-Ströme
  • Arrhythmogene Aktionspotenzialänderungen und DADs wurden abgeschwächt

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Circulation Research, erschienen am 06.07.2026. Verfasst von Bence Hegyi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of California, Davis (B.H., P.A., H.M.N., S.G., V.A.A., C.E.R.S., L.W., C.M.R., J.L.M., K.S.G., D.M.B.). Hauptthemen laut MEDLINE: Myocytes, Cardiac, Heart Failure, Arrhythmias, Cardiac, Sodium Channels. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIA NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Enhanced late Na + current (I Na,L ) in heart failure (HF) contributes to cardiomyocyte proarrhythmia. In addition to CaMKII (Ca 2+ /calmodulin-dependent protein kinase II), FGF (fibroblast growth factor) homologous factors 1–4 (FHF1–4) also modulate I Na,L , and targeting these pathways may provide benefits in HF. METHODS: Reverse-transcriptase quantitative polymerase chain reaction analysis of cardiac Na + channel and FHF splice isoforms was performed in human arrhythmogenic HF with reduced ejection fraction (HFrEF) and in translational animal models of HFrEF and HF with preserved ejection fraction (HFpEF). We tested the effects of an engineered peptide, FixR (FHF inhibiting x region), on cardiomyocyte I Na,L and electrophysiology in rabbit HFrEF and murine models of HFrEF and HFpEF. We also tested the in vivo electrophysiological effects of FixR via adenoviral delivery in transgenic mice with cardiomyocyte-specific overexpression of CaMKIIδ C . RESULTS: Expression of key FHF long isoforms (FHF1 A in humans, FHF2 S in rabbits, and FHF2 VY in mice) that have inhibitory effects on I Na,L was reduced in human, rabbit, and murine failing hearts. I Na,L was markedly enhanced in both HFrEF and HFpEF, and the FixR cell-penetrating peptide significantly reduced pathological I Na,L in both forms of HF. FixR had no effect on transient peak Na + current, L-type Ca 2+ current, or major K + currents in rabbit ventricular myocytes. FixR markedly attenuated proarrhythmogenic action potential changes (increased action potential duration, short-term variability, and alternans susceptibility) and delayed afterdepolarizations in both rabbit and murine HFrEF and HFpEF cardiomyocytes. These cellular antiarrhythmic effects were mimicked by the selective I Na,L inhibitor GS967 and the CaMKII inhibitor AIP (autocamtide-2 inhibitory peptide). FixR also attenuated QT prolongation and in vivo arrhythmia susceptibility in transgenic mice with cardiomyocyte-specific overexpression of CaMKIIδ C . CONCLUSIONS: In HF, I Na,L is increased, and FHF splice isoform expression is altered, allowing a novel mechanism to therapeutically target I Na,L . FixR, an FHF1 A -derived peptide, is a potent and selective I Na,L inhibitor and has antiarrhythmic properties in both HFrEF and HFpEF cardiomyocytes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacHeart FailureArrhythmias, CardiacSodium ChannelsMuscle ProteinsFibroblast Growth FactorsSodiumAnti-Arrhythmia AgentsAnimalsHumansRabbitsCalcium-Calmodulin-Dependent Protein Kinase Type 2Mice, TransgenicAction PotentialsMiceMaleDisease Models, Animal

Stichwörter der Autor:innen

action potentialsarrhythmias, cardiacelectrophysiologyheart failuresodium channels

Substanzen

Calcium-Calmodulin-Dependent Protein Kinase Type 2Sodium ChannelsMuscle ProteinsFibroblast Growth FactorsSodiumAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Pharmacology, University of California, Davis (B.H., P.A., H.M.N., S.G., V.A.A., C.E.R.S., L.W., C.M.R., J.L.M., K.S.G., D.M.B.).
  • Department of Physiology and Cellular Biophysics, Columbia University, New York, NY (N.C., R.W.M., L.F., M.B.-J.).
  • Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.C.B., K.B.M.).

ORCID-Profile: Bence Hegyi, Paweorn Angsutararux, Nourdine Chakouri, Lucile Fossier, Hai M Nguyen, Victor Alencar Almeida, Charlotte E R Smith, Lianguo Wang, Crystal M Ripplinger, Jody L Martin, Kenneth C Bedi, Kenneth B Margulies, Manu Ben-Johny, Donald M Bers

Förderung

  • NHLBI NIH HHS
  • NIA NIH HHS

Zitieren

APA

Hegyi, B., Angsutararux, P., Chakouri, N., Mahling, R. W., Fossier, L., Nguyen, H. M., Gilhooly, S., Almeida, V. A., Smith, C. E. R., Wang, L., Ripplinger, C. M., Martin, J. L., Ginsburg, K. S., Bedi, K. C., Margulies, K. B., Ben-Johny, M., & Bers, D. M. (2026). Targeting Arrhythmogenic Late Sodium Current by FHF1 A -Derivative FixR in Heart Failure Cardiomyocytes. Circulation Research, 139(2). https://doi.org/10.1161/circresaha.126.328204

Vancouver

Hegyi B, Angsutararux P, Chakouri N, Mahling RW, Fossier L, Nguyen HM, et al. Targeting Arrhythmogenic Late Sodium Current by FHF1 A -Derivative FixR in Heart Failure Cardiomyocytes. Circulation Research. 2026;139(2). doi:10.1161/circresaha.126.328204

BibTeX
@article{Hegyi2026,
  author = {Hegyi, Bence and Angsutararux, Paweorn and Chakouri, Nourdine and Mahling, Ryan W and Fossier, Lucile and Nguyen, Hai M and Gilhooly, Shannon and Almeida, Victor Alencar and Smith, Charlotte E R and Wang, Lianguo and Ripplinger, Crystal M and Martin, Jody L and Ginsburg, Kenneth S and Bedi, Kenneth C and Margulies, Kenneth B and Ben-Johny, Manu and Bers, Donald M},
  title = {Targeting Arrhythmogenic Late Sodium Current by FHF1 A -Derivative FixR in Heart Failure Cardiomyocytes},
  journal = {Circulation Research},
  year = {2026},
  volume = {139},
  number = {2},
  doi = {10.1161/circresaha.126.328204}
}
Kostenlos starten →